234 related articles for article (PubMed ID: 37439808)
21. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
[TBL] [Abstract][Full Text] [Related]
23. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of ALK5 inhibition in myelofibrosis.
Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
26. Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Cancer; 2012 Feb; 118(4):870-7. PubMed ID: 21766300
[TBL] [Abstract][Full Text] [Related]
27. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
28. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis.
Gowin K; Kosiorek H; Dueck A; Mascarenhas J; Hoffman R; Reeder C; Camoriano J; Tibes R; Gano K; Palmer J; Mesa R
Leuk Res; 2017 Sep; 60():31-35. PubMed ID: 28646676
[TBL] [Abstract][Full Text] [Related]
29. The new landscape of therapy for myelofibrosis.
Gowin K; Emanuel R; Geyer H; Mesa RA
Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
[TBL] [Abstract][Full Text] [Related]
30. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
31. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
[TBL] [Abstract][Full Text] [Related]
33. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
35. New drugs for the treatment of myelofibrosis.
Mesa RA
Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of ruxolitinib for myelofibrosis.
Santos FP; Verstovsek S
Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
[TBL] [Abstract][Full Text] [Related]
37. Hmga2 promotes the development of myelofibrosis in Jak2
Dutta A; Hutchison RE; Mohi G
Blood; 2017 Aug; 130(7):920-932. PubMed ID: 28637665
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
[TBL] [Abstract][Full Text] [Related]
39. Beyond JAK inhibitor therapy in myelofibrosis.
Odenike O
Hematology Am Soc Hematol Educ Program; 2013; 2013():545-52. PubMed ID: 24319230
[TBL] [Abstract][Full Text] [Related]
40. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]